The pharmaceutical industry is ready to fall off a cliff — a “patent cliff.” Over the next few years, some of the world’s most popular and lucrative medicines will go off patent, and generic competition will siphon an estimate…
From October 2010 to February 2011, biotech Clinical Data’s stock doubled, mostly thanks to FDA approval of its novel antidepressant. But also pushing the stock up — and making it likely to perhaps double again — is speculati…
To get potentially lifesaving drugs to patients faster, the U.S. Food and Drug Administration is allowed to approve some drugs — those that address unmet medical needs — based on fewer trials than usual. But it turns out that…
Pfizer reported fourth-quarter earnings on Tuesday that nearly quadrupled from a year ago as revenue rose 6%. But it also lowered its sales guidance for 2012, due to some of its bestselling drugs going off patent. What’s ahead …
Sanofi-Aventis announced its cancer drug candidate iniparib failed in a late-stage clinical trial. Other pharmaceutical companies have also experienced recent setbacks as they scramble to bolster their pipelines ahead of the pa…